Palantir Technologies finds itself at a familiar crossroads: delivering robust operational growth while wrestling with persistent skepticism over its sky-high valuation. As the data analytics firm prepares to report first-quarter results on May 4 after the U.S. market close, the gap between its business performance and stock price remains a central theme for investors.

The upcoming figures are highly anticipated. Management has forecast Q1 revenue between $1.532 billion and $1.536 billion, representing growth of approximately 60 percent year-over-year. Wall Street’s consensus is looking for adjusted earnings per share of $0.28 to $0.29. A key focus will be the U.S. commercial segment, which surged 137 percent in the prior quarter. Analysts are keen to see if Palantir’s Artificial Intelligence Platform (AIP) can sustain similarly impressive margins.

This strong fundamental progress, however, is set against a backdrop of analyst caution. Mizuho Securities recently adjusted its outlook, lowering the price target on Palantir from $195 to $185 on April 14, while maintaining an "Outperform" rating. This move is part of a broader reassessment of software stocks, a sector that has lagged the overall market by about 40 percentage points since February 2025. Palantir itself continues to trade at a significant premium, with a price-to-sales multiple of 80 and a price-to-earnings ratio around 215.

The stock’s recent performance reflects this tension. Shares recently climbed 4.73 percent to 120.54 EUR in one session, yet they remain down nearly 16 percent since the start of the year. The current price sits roughly 33 percent below its all-time high from November and is distant from its 52-week high of 179.86 EUR. The average price target among Wall Street analysts stands at $197.32, but prominent skeptics like investor Michael Burry see fair value below $50, citing growing competition from AI rivals like Anthropic.

Operationally, the company’s defense business provides a sturdy foundation. In April 2026, former President Trump publicly praised the software's military capabilities, a signal interpreted as ongoing U.S. government support for defense AI. Platforms like Gotham and Maven Smart System remain central to U.S. forces, backed by a $100 million framework contract extension secured in 2024. Further bolstering this segment, a three-year contract worth £240.6 million with the UK Ministry of Defence is set to begin this month and run through March 2029.

Simultaneously, Palantir’s commercial expansion is accelerating rapidly. Revenue from U.S. commercial customers doubled in 2025 to $1.5 billion. The company’s aggressive "Boot Camp" sales strategy is paying dividends, enabling it to complete complex software migrations in just two weeks. For the full year 2026, management is targeting revenue of up to $7.2 billion, which would equate to 61 percent growth.

Major investors are positioning themselves in contrasting ways. Cathie Wood’s ARK Invest purchased shares worth approximately $11 million in April. Other institutional players have moved in the opposite direction; Massachusetts Financial Services reduced its holdings significantly, and McGuire Investment Group cut its position by 4.2 percent to 205,289 shares.

Beyond valuation and growth, a new report from the British Medical Journal is applying subtle pressure. It questions the data foundation underpinning Palantir’s controversial £330 million contract with the UK's National Health Service (NHS). Should this criticism gain political traction, it could jeopardize that contract framework and weaken a key pillar of Palantir’s "Sovereign AI" strategy.

The company’s financials from the end of 2025 underscore its powerful momentum: total revenue jumped 70 percent to $1.41 billion in the fourth quarter, U.S. revenue grew 93 percent on strong government and commercial demand, and the total contract backlog soared 138 percent to $4.3 billion. As Palantir approaches its earnings date, the core question is whether this operational engine can finally convince the market that its premium valuation is justified, or if the reset in software stock prices has further to run.

Ad

Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.